Brief introduction:Deemed to have completed the Quality Consistency Evaluation. This product is suitable for the treatment of chronic hepatitis B in adults and adolescents (aged 12 years and above, weight at least 35kg).
Brief introduction:First approved generics in Chinese market; Indicated for the treatment of moderate to severe dementia of the Alzheimer’s type (Alzheimer's Disease).